Impact of body mass index on clinical outcomes in triple‐negative breast cancer
Open accessThe DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Obesity is associated with poorer outcomes in patients with hormone receptor‐positive breast cancers. This association is not well established for women with triple‐negative breast cancers (TNBC). In this study, the prognostic effects of body mass index on clinical outcome were evaluated in patients with TNBC. METHODS: A retrospective study was conducted on 418 patients who were treated between July 1996 and July 2010 for TNBC. Recurrence‐free survival (RFS) and overall survival (OS) were evaluated in relation to body mass index (BMI) after controlling for clinically significant variables. RESULTS: One hundred twenty‐four patients (29.7%) were normal/underweight (BMI ≤24.9 kg/m 2), 130 patients (31.1%) were overweight (BMI from 25 to 29.9 kg/m 2), and 164 patients (39.2%) were obese (BMI ≥30 kg/m 2). At a median follow‐up of 37.2 months, there were 105 recurrences (25.1%) and 87 deaths (20.8%). Compared with normal/underweight patients, the multivariate hazard ratio (HR) for RFS was 0.81 (95% confidence interval [CI], 0.49‐1.34) for obese patients. Similarly, OS was not associated with BMI category; obese patients had an HR of death of 0.94 (95% CI, 0.54‐1.64) compared with normal/underweight patients. A Cox regression analysis identified the receipt of chemotherapy (HR, 0.25; 95% CI, 0.12‐0.52), ductal histology (HR, 0.49; 95% CI, 0.25‐0.97), stage III disease (HR, 3.5; 95% CI, 1.35‐9.06), and increasing tumor size (HR, 1.19; 95% CI, 1.09‐1.3) as independent prognostic factors for OS. CONCLUSIONS: No significant relation between obesity and RFS or OS emerged in patients with TNBC after controlling for clinically significant factors. Cancer 2011;. © 2011 American Cancer Society.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Triple-negative breast cancer: clinical features and patterns of recurrence
Dent, R., Trudeau, M., Pritchard, K. I., Hanna, W. M., Kahn, H. K., Sawka, C. A., Lickley, L. A., Rawlinson, E., Sun, P., & Narod, S. A. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-3045 · Cited by 5,091 · cited 1×
“Compared with non-TNBC, these lesions generally occur in younger black women, are of a higher grade, have a higher propensity to metastasize to distant visceral organs, and have a worse outcome with a high rate of recurrences after adjuvant treatments.(4) A variety of factors, including stage, grade, age at diagnosis,…”
Background
Cited by
Chan, D. S. M., Vieira, A. R., Aune, D., Bandera, E. V., Greenwood, D. C., McTiernan, A., Navarro Rosenblatt, D., Thune, I., Vieira, R., & Norat, T. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu042 · Cited by 1,165
“[30,93,94,98,99,109-111] had an average follow-up of more than five years.”
BackgroundPicon‐Ruiz, M., Morata‐Tarifa, C., Valle‐Goffin, J. J., Friedman, E. R., & Slingerland, J. M. (2017) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21405 · Cited by 893
Petrelli, F., Cortellini, A., Indini, A., Tomasello, G., Ghidini, M., Nigro, O., Salati, M., Dottorini, L., Iaculli, A., Varricchio, A., et al. (2021) · JAMA Network Open · doi:10.1001/jamanetworkopen.2021.3520 · Cited by 530
Health and Racial Disparity in Breast Cancer
Yedjou, C. G., Sims, J. N., Miele, L., Noubissi, F., Lowe, L., Fonseca, D. D., Alo, R. A., Payton, M., & Tchounwou, P. B. (2019) · Advances in Experimental Medicine and Biology · doi:10.1007/978-3-030-20301-6_3 · Cited by 509
Obesity and Breast Cancer Prognosis: Evidence, Challenges, and Opportunities
Jiralerspong, S., & Goodwin, P. J. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.68.4480 · Cited by 405
Metadata
- Authors
- Ademuyiwa, F. O., Groman, A., O'Connor, T., Ambrosone, C., Watroba, N., & Edge, S. B.
- Venue
- Cancer
- Publisher
- Wiley
- Published
- 2011-03-08
- Volume
- 117
- Issue
- 18
- Pages
- 4132-4140
- ISSN
- 0008-543X (ISSN-L)
- 1097-0142
- OpenAlex
- W2038531693
- Cited by
- 101
- References
- 1
- FWCI
- 3.03
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.